×

Engineered immunoglobulin FC polypeptides

  • US 8,952,132 B2
  • Filed: 02/06/2012
  • Issued: 02/10/2015
  • Est. Priority Date: 02/07/2011
  • Status: Active Grant
First Claim
Patent Images

1. A polypeptide comprising an aglycosylated antibody human variant IgG Fc domain capable of binding a human Fcγ

  • RIIa polypeptide, wherein the Fc domain comprises an S298G and T299A amino acid substitutions at amino acids 298 and 299, wherein the numbering of the residues in the Fc domain is that of the EU index as in Kabat, and further wherein the variant IgG Fc domain comprises at least one additional substitution selected from the group consisting of;

    a) E382V and V263E;

    b) E382V, N390D and M428L;

    c) K392E, E382V, V397M and M428L;

    d) N315D, E382V and M428L, or e) H268P, E294K, N361S, E382V and M428L.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×